Loading…
Pacira BioSciences, Inc.
Pacira BioSciences, Inc. (PCRX) is listed on NASDAQ and classified in Drug Manufacturers - Specialty & Generic, part of the Healthcare sector. It is headquartered in Brisbane, United States and has 825 employees. The company is worth $1.45B and trades at 103.8x its earnings of the last twelve months; the median for its sector is 24.3x. Revenue was $726.41M in fiscal 2025, up 3.6% from the year before. Net income was $7.03M. The share price is within 3% of its 52-week high. 5 of the 38 superinvestors we track held it at the end of Q2 2026. The largest position belongs to Renaissance Technologies, at $43.99M. In that quarter, 2 of them opened or added to the position and 2 reduced it. Over the last 30 days, company insiders sold $217.92K of its stock on the open market and bought none. All of those sales were scheduled in advance under 10b5-1 plans.
Written from the data on this page: SEC filings (13F, Form 4, annual reports) and market prices.
Year by year, from the annual reports; dividends from the payments themselves.
Bars are year-end balances; lines are what happened during the year.
Major managers that reported this stock in their latest 13F.
▼ -30.9% over 5Y.
today you would have $695.10▼ -30.5%
Dividends reinvested, splits accounted for. Past prices say what happened, not what will.
The last 15 closed years, each at that year’s closing price and reported numbers.
| Indicator | Median | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Year-end price | $25.88 | $18.84 | $33.74 | $38.61 | $60.17 | $59.84 | $45.30 | $43.02 | $45.65 | $32.30 | $76.79 | $88.66 | $57.49 | $17.47 | $8.65 | |
| P/E | 65.4x | 161.7x | — | 37.9x |
Seven formulas applied to the reported numbers, each with its assumption next to the result. None of them predicts a price.
Square root of 22.5 × earnings × book value. Blind to intangibles, so it undervalues software and brands.
This formula has no meaning here — usually a loss, negative cash flow, or a missing input.
Median P/E of 24.3 among peers in the sector.
Median P/E of 65.4 across this company’s own years on record.
Cash flow growing 5.0% a year for 10 years, discounted at 10%, then 2.5% forever.
Sector median of 14.1x operating profit, less net debt. Banks have no EBITDA.
This formula has no meaning here — usually a loss, negative cash flow, or a missing input.
Companies of similar size in Healthcare, for comparison. The columns are the same ones above, in the same order.
| Stock | Price | P/E | P/B | Dividend yield | ROE | Market cap |
|---|---|---|---|---|---|---|
| OCULOcular Therapeutix Inc | $6.61 | — | 2.8x | 0.00% | -72.99% | $1.45B |
| KLRAKailera Therapeutics, Inc. | $11.25 | — | 1.3x | 0.00% | — | $1.46B |
| ETONEton Pharmaceuticals, Inc. | $50.31 | 125.8x | 30.5x | 0.00% | 35.97% | $1.44B |
| ANABAnaptysbio Inc | $48.10 |
| 113.6x |
| 65.4x |
| 18.0x |
| — |
| — |
| — |
| — |
| 1919.8x |
| — |
| — |
| — |
| — |
| P/S | 5.3x | 1.4x | 1.2x | 2.3x | 2.7x | 5.0x | 6.1x | 4.5x | 5.3x | 6.5x | 4.4x | 11.4x | 16.3x | 22.7x | 14.6x | 14.0x |
| P/B | 5.4x | 1.5x | 1.1x | 1.8x | 2.3x | 3.7x | 4.2x | 5.4x | 5.5x | 6.6x | 5.5x | 13.0x | 18.8x | 47.0x | 8.7x | 4.6x |
| EPS | $0.16 | -$2.15 | $0.89 | $0.34 | $0.92 | $3.33 | -$0.27 | -$0.01 | -$1.07 | -$1.02 | $0.04 | -$0.39 | -$1.93 | -$1.72 | -$2.64 |
| Profit margin | -2.62% | 0.97% | -14.20% | 6.22% | 2.39% | 7.75% | 33.87% | -2.62% | -0.14% | -14.87% | -13.73% | 0.75% | -6.94% | -74.70% | -133.77% | -276.17% |
| ROE | -3.10% | 1.01% | -12.79% | 4.82% | 2.05% | 5.75% | 23.48% | -3.10% | -0.15% | -15.25% | -17.33% | 0.85% | -8.01% | -154.93% | -79.39% | -89.76% |
Median of the years shown; P/E years above 200x are left out.
The average of the method families that answered, not of the seven numbers: four of the seven start from the same earnings per share.
5 methods answered, across 3 families.
Room for errors in the reported numbers.
-10.7% from the average.
Models, not forecasts, and not investment advice. How each formula works →
| — |
| 135.1x |
| 0.00% |
| — |
| $1.44B |
| AAPGAscentage Pharma Group International | $15.37 | — | 17.2x | 0.00% | -236.63% | $1.44B |
| INBXInhibrx Biosciences, Inc. | $97.10 | — | — | 0.00% | -1773.60% | $1.43B |